Under the US Food and Drug Administration (FDA) rare disease endpoint advancement pilot program (RDEA), preference will be given to applications with well-developed efficacy endpoints that can be ...
Late-stage cancer incidence may be a suitable alternative endpoint to cancer-specific mortality in lung and ovarian cancer screening trials, but not in breast, colorectal, or prostate cancer screening ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results